Applied Genetic Technologies Corporation (AGTC) was a clinical-stage biotechnology company dedicated to developing and commercializing gene therapies for rare and debilitating ophthalmic, otologic, and central nervous system (CNS) diseases. AGTC's proprietary gene therapy platform aimed to deliver AAV (adeno-associated virus)-based therapies to provide long-lasting and transformative benefits to patients. Key programs focused on X-linked retinitis pigmentosa (XLRP) and achromatopsia. In November 2022, AGTC was acquired by Syncona Limited, a leading healthcare investment company, and now operates as a part of Syncona's portfolio, continuing its mission to advance genetic medicines.
The Alachua headquarters served as the core for AGTC's research and development activities, clinical program oversight, manufacturing process development, and corporate operations.
The facilities included state-of-the-art laboratories designed for gene therapy research, development, and small-scale cGMP manufacturing capabilities, located within Progress Corporate Park, fostering collaboration with other biotech entities.
AGTC fostered a highly collaborative, science-driven, and patient-focused work culture. The environment encouraged innovation and dedication among its team of scientists, researchers, and professionals aiming to address significant unmet medical needs.
This location was pivotal for AGTC's scientific advancements, housing the intellectual capital and infrastructure necessary for developing its pipeline of AAV-based gene therapies from discovery through clinical trials.
Prior to its acquisition, AGTC's global presence was primarily characterized by its international clinical trial activities for its gene therapy candidates. This involved collaborations with clinical sites and investigators in North America and Europe. The company also engaged with global regulatory bodies like the FDA and EMA. While its physical operational footprint was centered in the US, its research impact and patient recruitment efforts were international.
14193 NW 119th Terrace, Suite 10, Progress Corporate Park
Alachua
Florida
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AGTC' leadership includes:
AGTC has been backed by several prominent investors over the years, including:
Applied Genetic Technologies Corporation (AGTC) was acquired by Syncona Ltd. in November 2022 and its operations were integrated. As a result, AGTC no longer functions as an independent company with its own executive team. Key leadership changes primarily occurred around the time of the acquisition, which falls outside the May 2023 - May 2024 period. No AGTC-specific executive hires or exits have been announced in the last 12 months under the AGTC banner.
Discover the tools AGTC uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While AGTC is now part of Syncona, a common email format used by AGTC prior to its acquisition was likely [first_initial][last_name]@[company_domain].com. For example, jdoe@agtc.com. This is a standard convention in many corporations, particularly in the biotech sector.
[first_initial][last]@agtc.com
Format
swasher@agtc.com
Example
70%
Success rate
Syncona Press Release • November 28, 2022
Syncona Limited announced the successful completion of its acquisition of Applied Genetic Technologies Corporation (AGTC) for $0.73 per share in cash. This strategic move enhances Syncona's gene therapy portfolio with AGTC's AAV-based therapeutic candidates for rare ophthalmic diseases....more
Syncona Portfolio Update • July 26, 2023
In its portfolio update, Syncona detailed ongoing development efforts for the gene therapy programs acquired from AGTC, including those for X-linked Retinitis Pigmentosa (XLRP) and Achromatopsia. Syncona emphasized its commitment to advancing these promising therapies towards clinical milestones....more
Syncona Full Year Results • May 23, 2024
Syncona's full-year results for the period ending March 31, 2024, reported on the strategic execution across its portfolio, including the gene therapy assets from AGTC. The company noted continued investment and progress in the clinical development pathways for these programs, aiming to deliver value and new treatments for patients....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AGTC, are just a search away.